The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•23 March 2026•

1 min read

Anavex Life Sciences Reports Positive Long-Term Data for Alzheimer's Treatment

Key Facts

1New data for blarcamesine demonstrated a consistent correlation between treatment effect and brain volume preservation in early Alzheimer's patients.

2Long-term clinical data indicated 17.8 months of time saved compared to the control group after 144 weeks of treatment.

Version History

2 additional sources confirmed this story

Anavex Life Sciences Corp. (AVXL) presented encouraging long-term data from its Phase IIb/III trials for blarcamesine, an oral treatment for early Alzheimer's disease. The results, shared at the AD/PD 2026 Conference, demonstrated a consistent correlation between the treatment and the preservation of brain volume in patients. Clinical data spanning 144 weeks indicated that patients receiving the drug saved approximately 17.8 months of disease progression compared to the control group. Experts highlighted the convenience of the oral medication, which could offer a significant advantage over existing injectable therapies. These findings reinforce the drug's potential efficacy and support the company's path toward regulatory approval. Investors view this milestone as a positive step for the biotech firm's neurodegenerative disease pipeline, potentially impacting its market valuation.